ORCHPHARMA2026-01-012026-03-31ORCHPHARMA2026-03-31ORCHPHARMA2025-03-31ORCHPHARMA2025-04-012026-03-31ORCHPHARMA2026-01-012026-03-31in-capmkt:OtherExpenses1MemberORCHPHARMA2025-04-012026-03-31in-capmkt:OtherExpenses1MemberORCHPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain1ORCHPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain2ORCHPHARMA2026-03-31OtherNoncurrentAssetsDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialAssetsDomain1ORCHPHARMA2026-03-31OtherCurrentAssetsDomain1ORCHPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1ORCHPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain2ORCHPHARMA2026-03-31OtherCurrentLiabilitiesDomain1ORCHPHARMA2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ORCHPHARMA2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain1ORCHPHARMA2025-12-31RelatedPartyTransactionDomain1ORCHPHARMA2026-03-31RelatedPartyTransactionDomain1ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain2ORCHPHARMA2025-12-31RelatedPartyTransactionDomain2ORCHPHARMA2026-03-31RelatedPartyTransactionDomain2ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain3ORCHPHARMA2025-12-31RelatedPartyTransactionDomain3ORCHPHARMA2026-03-31RelatedPartyTransactionDomain3ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain4ORCHPHARMA2025-12-31RelatedPartyTransactionDomain4ORCHPHARMA2026-03-31RelatedPartyTransactionDomain4ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain5ORCHPHARMA2025-12-31RelatedPartyTransactionDomain5ORCHPHARMA2026-03-31RelatedPartyTransactionDomain5ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain6ORCHPHARMA2025-12-31RelatedPartyTransactionDomain6ORCHPHARMA2026-03-31RelatedPartyTransactionDomain6ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain7ORCHPHARMA2025-12-31RelatedPartyTransactionDomain7ORCHPHARMA2026-03-31RelatedPartyTransactionDomain7ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain8ORCHPHARMA2025-12-31RelatedPartyTransactionDomain8ORCHPHARMA2026-03-31RelatedPartyTransactionDomain8ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain9ORCHPHARMA2025-12-31RelatedPartyTransactionDomain9ORCHPHARMA2026-03-31RelatedPartyTransactionDomain9ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain10ORCHPHARMA2025-12-31RelatedPartyTransactionDomain10ORCHPHARMA2026-03-31RelatedPartyTransactionDomain10ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain11ORCHPHARMA2025-12-31RelatedPartyTransactionDomain11ORCHPHARMA2026-03-31RelatedPartyTransactionDomain11ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain12ORCHPHARMA2025-12-31RelatedPartyTransactionDomain12ORCHPHARMA2026-03-31RelatedPartyTransactionDomain12ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain13ORCHPHARMA2025-12-31RelatedPartyTransactionDomain13ORCHPHARMA2026-03-31RelatedPartyTransactionDomain13ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain14ORCHPHARMA2025-12-31RelatedPartyTransactionDomain14ORCHPHARMA2026-03-31RelatedPartyTransactionDomain14ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain15ORCHPHARMA2025-12-31RelatedPartyTransactionDomain15ORCHPHARMA2026-03-31RelatedPartyTransactionDomain15ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain16ORCHPHARMA2025-12-31RelatedPartyTransactionDomain16ORCHPHARMA2026-03-31RelatedPartyTransactionDomain16ORCHPHARMA2026-01-012026-03-31RelatedPartyTransactionDomain17ORCHPHARMA2025-12-31RelatedPartyTransactionDomain17ORCHPHARMA2026-03-31RelatedPartyTransactionDomain17ORCHPHARMA2026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027ORCHID PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-08-142026-08-11INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-08-1414:00:002026-08-1418:15:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-01-18https://www.orchidpharma.com/investorsfalsefalseNot Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period. <br /> 2026-01-012026-03-31AuditedStandalone3683271000137281000382055200020983930004759000351234000263308000194970001118440006426860003491721000328831000-22020003266290000000326629000000032662900013027000339656000598852000105.455.45005.455.451. The above Revised results for the quarter and year ended March 31, 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 14, 2026.The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. <br /> <br /> 2. The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards (“Ind AS”) as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <br /> <br /> 3. a) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the ‘New Labour Codes’, which became effective from 21st November 2025. However, the new Rules are yet to be notified even as on date. <br /> During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711.27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under “Exceptional items”. <br /> Thereafter, based on subsequent FAQ’s and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to only Rs.733.29 Lakhs. Hence the additional provision of Rs.22.02 Lakhs has been provided in the March 2026 quarter under “Exceptional items”. The net impact of such re assessment has been appropriately accounted for in the statement of profit and loss. <br /> The Company continues to monitor the finalisation of Central / State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments. <br /> <br /> 4. 99,02,705 fully paid up Equity Shares of face value Rs. 10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. <br /> As on March 31, 2026 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <br /> <br /> Statement of QIP Net Funds raised and utilisation <br /> Particulars Amount as stated in Total amount utilised * Balance amount as on Remarks <br /> the Offer Document upto March 31, 2026 on March 31, 2026 kept <br /> Rs. In Lakhs(revised) Rs. In Lakhs in Fixed Deposits in lakhs <br /> <br /> 1)Investment in OBPL, subsidiary, <br /> for setting up Jammu <br /> Manufacturing Facility 13500 7302 6198 <br /> 2)Repayment/prepayment, in <br /> full or in part, of certain <br /> outstanding borrowings <br /> availed by the company 19546 19546 - <br /> 3)Funding capital expenditure <br /> requirements for setting up a <br /> new block at the API facility <br /> of the Company in Alathur, <br /> Tamil Nadu 36 36 - <br /> 4)General corporate purposes 6372 6372 0 # <br /> Total 39454 33256 6198 <br /> # As per QIP Offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakhs which was based on the propsoed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Agency Account was Rs. 39454 Lakhs as against the proposed Net Proceeds of Rs. 39180 Lakhs, therefore surplus Amount of Rs. 274 Lakhs has been included in GCP Balance as on June 30, 2026. The allocation among the objects has been revised vide Shareholder's Resolution dated September 20, 2025. <br /> *Balance amount excludes the interest earned on the Unutilized QIP funds kept in fixed deposits. <br /> <br /> 5. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable. <br /> <br /> 6. The figures for the quarters ended 31st March, 2026 and 31st March 2026 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. <br /> <br /> 7. In accordance to the provisions of Section 230-232 of the Companies Act, 2013 read with the applicable Rules made thereunder, the Board of Directors of Orchid Pharma Limited (“the Company” or “Transferee Company”) had approved the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited (“Dhanuka” or “Transferor Company”) and Orchid Pharma Limited and their respective shareholders and creditors (“the Scheme”), pursuant to which Dhanuka was proposed to be amalgamated with and into the Company, with April 01, 2024 as the Appointed Date. <br /> The Scheme was subsequently considered and sanctioned by the Hon’ble National Company Law Tribunal, Chennai Bench (“NCLT”) vide its order dated June 05, 2026. The Company obtained the certified copy of the said order and, upon filing of the same with the Registrar of Companies, Chennai, on July 10, 2026, the Scheme became effective (“Effective Date”). <br /> Pending receipt of the order of the Hon’ble NCLT and effectiveness of the Scheme, the financial results of the Company for the quarter and year ended March 31, 2026 were approved by the Board of Directors at its meeting held on May 25,2026, without giving effect to the Scheme. <br /> Subsequent to the approval of the financial results by the Board, the Scheme was sanctioned by the Hon’ble NCLT vide Order dated June 05, 2026 and which became effective on July 10, 2026. Accordingly, in accordance with the requirements of Appendix C to Ind AS 103 – Business Combinations, read with the applicable provisions of the Scheme, the amalgamation has been given effect to from the Appointed Date and the standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been revised/restated solely to give effect to the amalgamation. The corresponding comparative information has also been revised, wherever applicable, to give effect to the amalgamation from the Appointed Date. The revision includes the consequential impact of the amalgamation on the assets, liabilities, equity, reserves and other relevant financial statement items of the Company. <br /> The revision of the standalone and consolidated financial results has been carried out solely for giving effect to the aforesaid amalgamation pursuant to the Scheme, and no other adjustments have been made to the financial results originally approved by the Board of Directors on May 25, 2026, except for those consequentially arising from the accounting of the amalgamation. <br /> <br /> 8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29,2025 and August 01,2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. <br /> <br /> 9 The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, 2025. <br /> <br /> 10 Figures of the previous period have been regrouped/reclassified/restated wherever considered necessary.2025-04-012026-03-31AuditedStandalone1232778400056486900012892653000771391600016872000713839000114320500089615000433560000236211700012473124000419529000-73329000346200000000034620000000003462000001317600035937600059885200010158679070005.785.78005.785.78Other Expenses642686000Other Expenses23621170006650707000949977000005959000730798000008759220000182491000011540100028162330005981960004100730001216194300037231100000381350100013046000652083000010627000448925700006020170008814384000209763270005988520001586790700016466759000164667590003562980000004724800040354600013449300021155000559194000879088000102975000266083000027638050001728600036601790002821510008044000395037400000450956800020976327000Right to use Assets49289000Other financials assets66112000Other non current assets410073000Other current financial assets10627000Other current assets602017000lease liabilities47248000non-current liabilities21155000lease liabilities3854000Other current financial liabilities13432000Other current liabilities28215100089615000850543000-39605200006322300004536000001053380000004335600000-519800016465600000-73971000024424800000000620460000105404800014002480000-23955000000142420300000021169800000009110100017182460000000000000000742478000000800027682900001141309000-1163175000000000002561980005628750000010072200000-407399000-1463710000-14637100015941700013046000items that will not be recclassified as profit or loss1302700013027000items that will not be recclassified as profit or loss131760001317600000001302700013176000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanyPurchase of goods or services500000000Approved66404000054983000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanyAny other transactionlease rents recived25000000Approved1475400005583000Orchid Pharma Limited******Dhanuka Laboratories Limited******Holding CompanySale of goods or services500000000Approved18698200011345000198328000Orchid Pharma Limited******DHANUKA AGRITECH LIMITED******Related Party under sec2(76)(1v)Any other transactionlease rents paid15000000Approved4278000057000Orchid Pharma Limited******DHANUKA AGRITECH LIMITED******Related Party under sec2(76)(1v)Any other transactionrent deposit paidApproval included with lease rents019100000Orchid Pharma Limited******ORBION PHARMACEUTICALS PRIVATE LIMITED******Associate CompanySale of goods or services50000000Approved156700000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyLoan3500000000Approved40359100013130330001785881000Loan0.0012As per loan agreementUnsecuredFor investing in capital projectOrchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyInterest receivedAppoval included with loan given6925700000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly Owned Subsidiary companyAny other transactioncorporate gaurantee commission received60000000Approved33031000019551000Orchid Pharma Limited******OTSUKA CHEMICAL (INDIA) PVT LTD******Related Party under sec2(76)(1v)Purchase of goods or services4000000000Approved58510400098307000330211000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Purchase of goods or services10000000Approved32400010001000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Sale of goods or services50000000Approved30830007020001012000Orchid Pharma Limited******Synmedic Laboratories******Related Party under sec2(76)(iii)Any other transactionlease rents recived20000000Approved1004500003801000Orchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly Owned Subsidiary companyAny other transactionShare capital investedN.A028950002895000Orchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly owned Subsidiary companyLoanN.A38409000038409000Loan0.0006As per loan agreementUnsecuredFor meeting business requirementOrchid Pharma Limited******Orchid Pharma Europe GMBH******Wholly owned Subsidiary companyInterest receivedN.A6190000619000Orchid Pharma Limited******ORCHID BIO-PHARMA LIMITED******Wholly owned Subsidiary companyAny other transactionCorporate guarantee givenN.A258200000001675648000AuditedtrueSinghi & Co.true2028-08-31